ACM
CLRB icon

ACT Capital Management’s Cellectar Biosciences CLRB Stock Holding History

ACT Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$73K Hold
725
– – 0.1% 52
2022
Q2 		$88K Hold
725
– – 0.12% 52
2022
Q1 		$150K Hold
725
– – 0.16% 57
2021
Q4 		$144K Hold
725
– – 0.1% 76
2021
Q3 		$201K Hold
725
– – 0.1% 82
2021
Q2 		$259K Buy
+725
New +$314K 0.13% 81

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

ACT Capital Management's CLRB Position: Q3 2022 in Review

ACT Capital Management held its Cellectar Biosciences (CLRB) position steady in Q3 2022 at 725 shares worth $73K. The position accounts for 0.1% of the portfolio, ranked #52.

ACT Capital Management first reported a position in CLRB in Q2 2021 and has held it in 6 quarters since. The position peaked at $259K in Q2 2021. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2022.

  • ACT Capital Management held 725 shares of Cellectar Biosciences worth $73K as of Q3 2022.
  • ACT Capital Management left its Cellectar Biosciences share count unchanged in Q3 2022.
  • Cellectar Biosciences made up 0.1% of ACT Capital Management's portfolio in Q3 2022, its #52 holding.
  • ACT Capital Management first reported a position in Cellectar Biosciences in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Cellectar Biosciences position peaked at $259K in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.